Core Viewpoint - Xuan Bamboo Biotech-B (02575) has seen a nearly 3% increase in stock price, currently trading at 66.95 HKD, following the announcement of its innovative drug, Pirlosil, being included in the 2025 National Basic Medical Insurance Directory [1] Group 1: Company Announcement - On December 8, Xuan Bamboo Biotech-B announced that its self-developed innovative drug, Pirlosil tablets (brand name: Xuan Yuening®), has been included in the 2025 National Basic Medical Insurance Directory [1] - The 2025 National Basic Medical Insurance Directory will officially take effect on January 1, 2026 [1] Group 2: Market Impact - The inclusion of Pirlosil in the insurance directory is expected to enhance the affordability and accessibility of the drug for patients, which will facilitate its market promotion and increase sales scale [1] - The company plans to actively cooperate in implementing the insurance policy, continue to promote hospital access, expand core markets, and increase market coverage to improve patient access to medication [1]
港股异动 轩竹生物-B(02575)涨近3% 自研创新药轩悦宁®首次纳入2025国家基本医保目录